Economy/Home · Economy

Biosimilar-Related Stocks Mixed... Samsung Epis Holdings Up Over 5%, Samchundang Pharm Falls

Biosimilar-related stocks showed clearly diverging movements on the morning of the 17th. While some shares climbed as much as the 5% range, others turned lower, making stock-specific differentiation particularly pronounced. As of 11:33 a.m. on the 17th, Samsung Epis Holdings was trading at 375,500

Oseong Kwon
Staff Reporter
3 min read
Biosimilar-Related Stocks Mixed... Samsung Epis Holdings Up Over 5%, Samchundang Pharm Falls
CBC News

Biosimilar-related stocks showed clearly diverging movements on the morning of the 17th. While some shares climbed as much as the 5% range, others turned lower, making stock-specific differentiation particularly pronounced.

As of 11:33 a.m. on the 17th, Samsung Epis Holdings was trading at 375,500 won, up 5.33% from the previous day, leading the gainers. Hanall BioPharma also rose 4.53% to 53,100 won. Celltrion Pharm climbed 3.22% to 41,700 won, and Bionex gained 3.14% to 6,890 won. Hanmi Pharmaceutical likewise joined the upward trend, rising 2.35% to 457,000 won.

In addition, Dong-A ST (+2.19%), Green Cross (+2.03%), Alteogen (+1.92%), and Daewoong Pharmaceutical (+1.79%) were also trading higher, while Liscure Plus (+0.97%) and Chong Kun Dang (+0.49%) posted modest gains.

Meanwhile, some stocks weakened. Samchundang Pharmaceutical fell 1.63% from the previous day to 163,200 won. Aprogen (-0.99%), Sunbio (-0.79%), and Boryung (-0.23%) also declined. Celltrion remained flat at 214,500 won, unchanged from the previous session.

Overall, biosimilar-related stocks continued a mixed pattern on the day. Whether the gaining stocks can sustain their strength, or the declining names narrow their losses and rebound, is seen as a key point to watch going forward.

[※ This article is for investment reference purposes only, and investment decisions and any resulting responsibility rest with the investor.]

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.